Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Todor A. Popov, Sophie De Niet & Francis Vanderbist. (2016) Budesonide/salmeterol in fixed-dose combination for the treatment of asthma. Expert Review of Respiratory Medicine 10:2, pages 113-125.
Read now
Read now
Bruce M Prenner. (2007) Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 8:17, pages 3069-3084.
Read now
Read now
Mathieu Molimard, Denise Till, Stephan Stenglein, Dilraj Singh & Markus Krummen. (2007) Inhalation devices for long-acting β2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD. Current Medical Research and Opinion 23:10, pages 2405-2413.
Read now
Read now
Articles from other publishers (28)
Henry ChrystynWahida AzouzWalid Tarsin. (2023) Dry Powder Inhalers: From Bench to Bedside. Journal of Aerosol Medicine and Pulmonary Drug Delivery.
Crossref
Crossref
Wei-Ren Ke, Philip Chi Lip Kwok, Dipesh Khanal, Rachel Yoon Kyung Chang & Hak-Kim Chan. (2021) Co-spray dried hydrophobic drug formulations with crystalline lactose for inhalation aerosol delivery. International Journal of Pharmaceutics 602, pages 120608.
Crossref
Crossref
Wei-Ren Ke, Rachel Yoon Kyung Chang, Philip Chi Lip Kwok, Donghao Chen & Hak-Kim Chan. (2020) Spray drying lactose from organic solvent suspensions for aerosol delivery to the lungs. International Journal of Pharmaceutics 591, pages 119984.
Crossref
Crossref
S. Sommerfeld Ross, S. Gharse, L. Sanchez & J. Fiegel. (2017) Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication. International Journal of Pharmaceutics 531:1, pages 14-23.
Crossref
Crossref
Thaigarajan Parumasivam, Rachel Yoon Kyung Chang, Sharif Abdelghany, Tian Tian Ye, Warwick John Britton & Hak-Kim Chan. (2016) Dry powder inhalable formulations for anti-tubercular therapy. Advanced Drug Delivery Reviews 102, pages 83-101.
Crossref
Crossref
David PrimeWilfried de BackerMelanie HamiltonAnthony CahnAndrew PreeceDennis KelleherAmanda BainesAlison MooreNoushin BrealeyJackie Moynihan. (2015)
Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA
®
Dry Powder Inhaler
. Journal of Aerosol Medicine and Pulmonary Drug Delivery 28:6, pages 486-497.
Crossref
Crossref
Ahmed O. Shalash, Abdulla M. Molokhia & Mustafa M.A. Elsayed. (2015) Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content. European Journal of Pharmaceutics and Biopharmaceutics 96, pages 291-303.
Crossref
Crossref
Zhenbo Tong, Hidehiro Kamiya, Aibing Yu, Hak-Kim Chan & Runyu Yang. (2014) Multi-Scale Modelling of Powder Dispersion in a Carrier-Based Inhalation System. Pharmaceutical Research 32:6, pages 2086-2096.
Crossref
Crossref
Wahida AzouzPhilip ChetcutiHarold S.R. HoskerDinesh SaralayaJohn StephensonHenry Chrystyn. (2015) The Inhalation Characteristics of Patients When They Use Different Dry Powder Inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 28:1, pages 35-42.
Crossref
Crossref
Sandra Lindert, Antje Below & Joerg Breitkreutz. (2014) Performance of Dry Powder Inhalers with Single Dosed Capsules in Preschool Children and Adults Using Improved Upper Airway Models. Pharmaceutics 6:1, pages 36-51.
Crossref
Crossref
S. Weber, A. Zimmer & J. Pardeike. (2014) Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics 86:1, pages 7-22.
Crossref
Crossref
Darragh Murnane & Marc B. Brown. 2014. Pediatric Formulations. Pediatric Formulations
253
272
.
Suzanne M. D’Addio, John Gar Yan Chan, Philip Chi Lip Kwok, Bryan R. Benson, Robert K. Prud’homme & Hak-Kim Chan. (2013) Aerosol Delivery of Nanoparticles in Uniform Mannitol Carriers Formulated by Ultrasonic Spray Freeze Drying. Pharmaceutical Research 30:11, pages 2891-2901.
Crossref
Crossref
Z.B. Tong, B. Zheng, R.Y. Yang, A.B. Yu & H.K. Chan. (2013) CFD-DEM investigation of the dispersion mechanisms in commercial dry powder inhalers. Powder Technology 240, pages 19-24.
Crossref
Crossref
Gabriela Apiou-SbirleaSteve Newman, John Fleming, Ruediger Siekmeier, Stephan Ehrmann, Gerhard Scheuch, Guenther Hochhaus & Anthony Hickey. (2013) Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives. Therapeutic Delivery 4:3, pages 343-367.
Crossref
Crossref
Christopher J Cates & Matthew J Cates. (2012) Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Martin J. Donovan, Sin Hyen Kim, Venkatramanan Raman & Hugh D. Smyth. (2012) Dry Powder Inhaler Device Influence on Carrier Particle Performance. Journal of Pharmaceutical Sciences 101:3, pages 1097-1107.
Crossref
Crossref
Sadaf Matinkhoo, Karlene H. Lynch, Jonathan J. Dennis, Warren H. Finlay & Reinhard Vehring. (2011) Spray-dried Respirable Powders Containing Bacteriophages for the Treatment of Pulmonary Infections. Journal of Pharmaceutical Sciences 100:12, pages 5197-5205.
Crossref
Crossref
Gur Jai Pal Singh & Guirag Poochikian. 2011. Controlled Pulmonary Drug Delivery. Controlled Pulmonary Drug Delivery
489
527
.
Maria H. Bussamra, Rafael Stelmach, Joaquim C. Rodrigues & Alberto Cukier. (2009) A randomized, comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting. Annals of Allergy, Asthma & Immunology 103:3, pages 248-253.
Crossref
Crossref
Christopher J Cates, Matthew J Cates & Toby J Lasserson. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Carl P. CriéeThomas MeyerWolfgang PetroKnut SommererPeter Zeising. (2006)
In Vitro
Comparison of Two Delivery Devices for Administering Formoterol: Foradil
®
P and Formoterol Ratiopharm Single-Dose Capsule Inhaler
. Journal of Aerosol Medicine 19:4, pages 466-472.
Crossref
Crossref
G.K. Crompton, P.J. Barnes, M. Broeders, C. Corrigan, L. Corbetta, R. Dekhuijzen, J.C. Dubus, A. Magnan, F. Massone, J. Sanchis, J.L. Viejo & T. Voshaar. (2006) The need to improve inhalation technique in Europe: A report from the Aerosol Drug Management Improvement Team. Respiratory Medicine 100:9, pages 1479-1494.
Crossref
Crossref
David Pearlman, Henry Milgrom, Denise Till & Barbara Ziehmer. (2006) Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children. Annals of Allergy, Asthma & Immunology 97:3, pages 382-388.
Crossref
Crossref
H.-Y. Li, P. C. Seville, I. J. Williamson & J. C. Birchall. (2005) The use of absorption enhancers to enhance the dispersibility of spray-dried powders for pulmonary gene therapy. The Journal of Gene Medicine 7:8, pages 1035-1043.
Crossref
Crossref
Alexander G. ChuchalinAhmed I. ManjraNadezhda N. RozinovaOlga SkopkováGiovanni Della CioppaDenise TillGuenther KaiserTaiwo FasholaJohn Kottakis. (2005)
Formoterol Delivered via a New Multi-Dose Dry Powder Inhaler (Certihaler
™
) Is as Effective and Well Tolerated as the Formoterol Dry Powder Inhaler (Aerolizer
®
) in Children with Persistent Asthma
. Journal of Aerosol Medicine 18:1, pages 63-73.
Crossref
Crossref
J. Bousquet, G. Huchon, V. Leclerc, E. Vicaut & G. Lefrançois. (2005) A Randomized, Double-Blind, Double-Dummy, Single-Dose, Efficacy Crossover Trial Comparing Formoterol-HFA (pMDI) versus Formoterol-DPI (Aerolizer<sup>TM</sup>) and Placebo (pMDI or Aerolizer<sup>TM</sup>) in Asthmatic Patients. Respiration 72:1, pages 6-12.
Crossref
Crossref
C. Vogelberg, H.-J. Kremer, B. Ellers-Lenz, M. Engel, J. Maus, F. Conrad & R. Hermann. (2004) Clinical evaluation of the peak inspiratory flow generated by asthmatic children through the Novolizer®. Respiratory Medicine 98:10, pages 924-931.
Crossref
Crossref